Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two...
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and...
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients Agency feedback from Type C meeting process supports the company’s proposed clinical development plans to expand the upliFT-D trial to...
TigerConnect Dominates G2’s Summer 2024 Rankings, Securing Top Positions in Healthcare Technology SANTA MONICA, CA., July 30, 2024 — TigerConnect, the leading clinical collaboration platform in healthcare, has once again demonstrated its industry leadership by...
BrightInsight Expands its Partnership with Google Cloud to Enhance the Patient Journey Through Generative AI BrightInsight is modernizing its development processes and patient companion apps with Google’s Gemini models, MedLM, and Vertex AI SAN JOSE, Calif. –...
Recent Comments